Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Anaptysbio (ANAB) Retained Earnings (2017 - 2025)

Anaptysbio (ANAB) has disclosed Retained Earnings for 9 consecutive years, with -$24000.0 as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Retained Earnings fell 107.87% year-over-year to -$24000.0, compared with a TTM value of -$24000.0 through Dec 2025, down 107.87%, and an annual FY2025 reading of -$24000.0, down 107.87% over the prior year.
  • Retained Earnings was -$24000.0 for Q4 2025 at Anaptysbio, down from $47000.0 in the prior quarter.
  • Across five years, Retained Earnings topped out at $759000.0 in Q3 2024 and bottomed at -$837.3 million in Q2 2025.
  • Average Retained Earnings over 5 years is -$219.4 million, with a median of -$3.6 million recorded in 2022.
  • The sharpest move saw Retained Earnings tumbled 106648.1% in 2022, then surged 132.3% in 2024.
  • Year by year, Retained Earnings stood at -$422000.0 in 2021, then crashed by 106648.1% to -$450.5 million in 2022, then plummeted by 36.32% to -$614.1 million in 2023, then soared by 100.05% to $305000.0 in 2024, then tumbled by 107.87% to -$24000.0 in 2025.
  • Business Quant data shows Retained Earnings for ANAB at -$24000.0 in Q4 2025, $47000.0 in Q3 2025, and -$837.3 million in Q2 2025.